A Phase I/II Study of OBI-3424 in Subjects With Advanced Solid Tumors

Solid Tumor Clinical Trial

Official title:

A Phase I/II Study of OBI-3424 in Subjects With Advanced Solid Tumors

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03592264
• Other study ID #: OBI-3424-001
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: June 7, 2018
• Est. completion date: March 21, 2024

Study information

• Verified date: April 2024
• Source: OBI Pharma, Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of OBI-3424 administered as a single agent.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 68
• Est. completion date: March 21, 2024
• Est. primary completion date: February 13, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria (all subjects):

1. At least 18 years of age

2. Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's Institutional Review Board (IRB)/Independent Ethics Committee (IEC)

3. Recovered from toxicities of prior therapy to Grade 0 or 1

4. Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) criteria

5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

6. Acceptable liver function:

1. Bilirubin =1.5 × institutional ULN

2. AST and ALT =3.0 × ULN, or =5.0 × ULN for subjects with liver involvement

7. Acceptable renal function:

a. Creatinine clearance >30 mL/min according to the Cockcroft-Gault formula

8. Acceptable hematologic status (without hematologic support, other than red blood cell

transfusion):

1. ANC =1500 cells/µL

2. Platelet count =100,000/µL

3. Hemoglobin =9.0 g/dL (prior packed red blood cell transfusion or erythropoietin support is allowed).

9. Females of childbearing potential must not have had unprotected sexual intercourse within 30 days before study entry and must agree to use a highly effective method of contraception (e.g., total abstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 30 days after study drug discontinuation.

Dose Escalation Phase Subjects Only (Inclusion Criteria):

10. Histologically or cytologically confirmed solid malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective

11. Tumor progression after most recent therapy

Expansion Phase Subjects Only (Inclusion Criteria):

12. Available tumor tissue, either archival or fresh (fresh preferred).

13. For treatment, an AKR1C3 IHC H-score of = 100 using a validated IHC assay in one of

the following tumor types to be enrolled in the respective cohort:

1. Cohort A: Pancreatic Adenocarcinoma

2. Cohort B: Basket (any solid tumor type other than pancreatic adenocarcinoma)

Exclusion Criteria:

1. Prior radiotherapy to more than 25% of the bone marrow

2. Symptomatic brain metastases, unless previously treated and well controlled for at least 4 weeks after central nervous system (CNS)-directed treatment as ascertained by clinical examination and brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT]) during the Screening Period. Patients with known leptomeningeal disease are excluded.

3. Previously treated malignancies, except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancers whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the current study

4. Patients with hepatocellular carcinoma (applies to Expansion Phase only)

5. Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without complete recovery

6. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy

7. Treatment with radiation therapy, surgery, chemotherapy, targeted therapies or hormones within 3 weeks prior to study entry (6 weeks for nitrosoureas or mitomycin C)

8. Concomitant use of strong CYP3A4 inhibitors/inducers

9. Concomitant use of naproxen within a 48-hour window before and after OBI-3424 dosing

10. Females who are pregnant or breast-feeding

11. Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study

12. Unwillingness or inability to comply with the study protocol for any reason

Related Conditions & MeSH terms

• Adenocarcinoma
• Pancreatic Adenocarcinoma
• Solid Tumor

Intervention

Drug:
• OBI-3424
liquid formulation for Intravenous infusion

Locations

Country	Name	City	State
United States	Ohio State University Comprehensive Cancer Center	Columbus	Ohio
United States	MD Anderson Cancer Center	Houston	Texas
United States	Scripps Clinic Torrey Pines	La Jolla	California
United States	USC Norris Comprehensive Cancer Center	Los Angeles	California
United States	Rutgers Cancer Institute of New Jersey	New Brunswick	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
OBI Pharma, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence and severity of adverse events (AEs)	Adverse events will be graded according to the Common Toxicity Criteria for Adverse Events (CTCAE) version 5.0.	Adverse events will be noted as it occurs. Timeframe for measure begins after first administration of study drug until 30 days after last dose of study drug. Study duration defined as up to 2 years from the first dose.
Primary	Assess safety changes in electrocardiogram (ECG)	Resting 12-lead ECGs will be obtained from all subjects' pre-OBI-3424 infusion and within 15 minutes post-OBI-3424 infusion in order to assess any impact OBI-3424 may have on the QT interval as assessed by the Fridericia's Correction Formula (QTcF).	Day 1 Cycles 1 and 2 (each cycle is 21 days)
Primary	Assess safety changes of body weight.	If during treatment a subject's body weight changes by >10%, the dose should be adjusted.	Day 1 of each cycle (there are 34 cycles; 21 days for each cycle)
Primary	Number of participants with dose limiting toxicities (DLTs)	A DLT is defined as the occurrence of Grade 3/4 adverse events within the first cycle (the first 21 days) of treatment that are considered by the investigator to be at least possibly related to OBI-3424.	Throughout Cycle 1 (21 days for each cycle)
Primary	Define the Recommended Phase 2 Dose (RP2D)	Determination of the MTD, based on the frequently of DLTs observed in Cycle 1 in subjects recruited to the Dose Escalation Phase.	Days 1 and 8 of each cycle (all 34 cycles and there are 21 days for each cycle)
Primary	Pharmacokinetics (PK) - Time to maximum concentration (Tmax)	Tmax of OBI-3424 and OBI-2660 will be computed for each subject where possible.	Days 1 and 8 of Cycle 1 (first cycle of 34 cycles and there are 21 days for each cycle)
Primary	PK - Maximum peak plasma concentration (Cmax)	Cmax of OBI-3424 and OBI-2660 will be computed for each subject where possible.	Days 1 and 8 of Cycle 1 (first cycle of 34 cycles and there are 21 days for each cycle)
Primary	PK - The magnitude of the slope of the linear regression of the log concentration vs. time profile during the terminal phase (Kel)	Kel of OBI-3424 and OBI-2660 will be computed for each subject where possible.	Days 1 and 8 of Cycle 1 (first cycle of 34 cycles and there are 21 days for each cycle)
Primary	PK - Half-life (T1/2)	T1/2 computed as ln (2)/Kel of OBI-3424 and OBI-2660 will be computed for each subject where possible.	Days 1 and 8 of Cycle 1 (first cycle of 34 cycles and there are 21 days for each cycle)
Primary	PK - Area under the concentration-time curve (AUClast)	AUClast from Hour 0 through the last quantifiable concentration time (LQCT), where LQCT is the time at which the last sample with a quantifiable concentration was drawn	Days 1 and 8 of Cycle 1 (Cycle 1 is 21 days)